Thrombolytic Therapy

• 

  Subject Areas on Research

  • "Code stroke": hospitalized versus emergency department patients. 
  • "Hugging balloons" through a single 8-French guide: salvage angioplasty with lytic therapy in the infarct vessel of a 40-year-old man. 
  • "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction. 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. 
  • A Smartphone-based Decision Support Tool Improves Test Performance Concerning Application of the Guidelines for Managing Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy. 
  • A canine model of acute coronary artery thrombosis for the evaluation of reperfusion strategies. 
  • A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 
  • A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. 
  • A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy. 
  • A geographic information system analysis of the impact of a statewide acute stroke emergency medical services routing protocol on community hospital bypass. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. 
  • A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. 
  • A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. 
  • A tale of two countries: Insights from the differences in Canadian/American patterns of care for patients with acute coronary syndromes. 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 
  • Aborted infarction: the ultimate myocardial salvage. 
  • Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. 
  • Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. 
  • Acute Limb Ischemia. 
  • Acute and chronic mesenteric ischemia. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute coronary syndromes. STREAMlining care for patients with STEMI. 
  • Acute coronary syndromes: introducing new therapies into established guidelines. 
  • Acute ischemic stroke treatment in 2007. 
  • Acute management of intracranial hemorrhage in patients receiving thrombolytic therapy: case reports. 
  • Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. 
  • Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. 
  • Adjunctive transcutaneous ultrasound with thrombolysis: results of the PLUS (Perfusion by ThromboLytic and UltraSound) trial. 
  • Advances in Stroke 2017. 
  • Advances in primary stroke prevention. 
  • Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. 
  • Aggressive therapy of acute MI in the elderly. 
  • American Society of Echocardiography Cardiovascular Technology and Research Summit: a roadmap for 2020. 
  • An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke. 
  • An analysis of the cause of early mortality after administration of thrombolytic therapy. The Thrombolysis Angioplasty in Myocardial Infarction Study Group. 
  • An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. 
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. 
  • Anesthesia for endovascular treatment of acute ischemic stroke. 
  • Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. 
  • Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. 
  • Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. 
  • Anticoagulation After Heart Valve Replacement or Transcatheter Valve Implantation. 
  • Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. 
  • Antithrombotic therapy after prosthetic cardiac valve implantation: improving postoperative, long-term patient management. Introduction. 
  • Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies. 
  • Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. 
  • Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. 
  • Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. 
  • Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. 
  • Assessment of the patient with hyperacute stroke: imaging and therapy. 
  • Association between ST segment Resolution following Fibrinolytic therapy or Intracoronary stenting, and Reinfarction in the same myocardial region in the DANAMI-2 study population. 
  • Association between stroke center hospitalization for acute ischemic stroke and mortality. 
  • Association of TIMI myocardial perfusion grade and ST-segment resolution with cardiovascular magnetic resonance measures of microvascular obstruction and infarct size following ST-segment elevation myocardial infarction. 
  • Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. 
  • Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. 
  • Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. 
  • At home thrombolysis. 
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. 
  • Atrioventricular and intraventricular conduction disorders in acute myocardial infarction: a reappraisal in the thrombolytic era. 
  • Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. 
  • Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis. 
  • Behavioral equipoise: a way to resolve ethical stalemates in clinical research. 
  • Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes. 
  • Biochemical markers of early reperfusion. 
  • Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. 
  • Bridging American-Canadian health care outcome differences: is there really a gap? 
  • CT patterns of intracranial hemorrhage complicating thrombolytic therapy for acute myocardial infarction. 
  • CT perfusion-guided versus time-guided mechanical recanalization in acute ischemic stroke patients. 
  • Canadian Consensus Conference on Coronary Thrombolysis--1994 update. 
  • Cancer and thrombosis: back to the future renewed interest in an old problem. 
  • Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. 
  • Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. 
  • Cardiologists' and emergency physicians' perspectives on and knowledge of reperfusion guidelines pertaining to ST-segment-elevation myocardial infarction. 
  • Cardiovascular research in the elderly: challenges, opportunities, and impact. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Catheter-directed thrombolysis: is it worth the risk? 
  • Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management. 
  • Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. 
  • Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. 
  • Characteristics, treatment and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. 
  • Charting the course of clinical research: from an inspired past to a promising future. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. 
  • Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke. 
  • Clinical Crossroads: a 36-year-old woman recuperating from stroke. 
  • Clinical Policy: Emergency Department Management of Patients Needing Reperfusion Therapy for Acute ST-Segment Elevation Myocardial Infarction. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical and economic lessons from studies of coronary thrombolysis. 
  • Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. 
  • Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. 
  • Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Clinical outcomes according to time to treatment. 
  • Clinical outcomes among stroke patients receiving tissue plasminogen activator therapy beyond the 3-hour time window. 
  • Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Clinical risks of thrombolytic therapy. 
  • Clinical trials in acute myocardial infarction: should we adjust for baseline characteristics? 
  • Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Coagulation markers and outcomes in acute coronary syndromes. 
  • Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. 
  • Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). 
  • Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). 
  • Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. 
  • Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. 
  • Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. 
  • Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. 
  • Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of inferior vena caval thrombosis. 
  • Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. 
  • Comparison of Acute Ischemic Stroke Care and Outcomes Between Comprehensive Stroke Centers and Primary Stroke Centers in the United States. 
  • Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of an automated thrombolytic predictive instrument to both diagnostic software and an expert cardiologist for diagnosis of an ST elevation acute myocardial infarction. 
  • Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. 
  • Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. 
  • Comparison of neurologic and radiographic outcomes with Solitaire versus Merci/Penumbra systems for acute stroke intervention. 
  • Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. 
  • Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. 
  • Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. 
  • Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. 
  • Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. 
  • Components and Trends in Door to Treatment Times for Endovascular Therapy in Get With The Guidelines-Stroke Hospitals. 
  • Computed tomography perfusion-based selection of patients for endovascular recanalization. 
  • Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India. 
  • Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. 
  • Contemporary Trends and Comparative Outcomes With Adjunctive Inferior Vena Cava Filter Placement in Patients Undergoing Catheter-Directed Thrombolysis for Deep Vein Thrombosis in the United States: Insights From the National Inpatient Sample. 
  • Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry®-Get With The Guidelines (GWTG)®. 
  • Contrast stasis on noncontrast computed tomography as a predictor of stroke postthrombolysis. 
  • Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group. 
  • Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. 
  • Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. 
  • Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. 
  • Cost-effectiveness analyses. 
  • Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group. 
  • Critical concepts in cost-effectiveness for cardiovascular specialists. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current status of percutaneous PFO closure. 
  • Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. 
  • Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke. 
  • Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. 
  • Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. 
  • Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. 
  • Development and initial testing of the stroke rapid-treatment readiness tool. 
  • Development and prognosis of non-Q-wave myocardial infarction in the thrombolytic era. 
  • Development of a research agenda for endovascular treatment of venous thromboembolism: proceedings from a multidisciplinary consensus panel. 
  • Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. 
  • Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. 
  • Differential mechanisms of failure of autogenous and non-autogenous bypass conduits: an assessment following successful graft thrombolysis. 
  • Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. 
  • Distinguishing between early and late responders to symptoms of acute myocardial infarction. 
  • Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. 
  • Does the early hazard phenomenon exist? Do the GUSTO findings prove or disprove? 
  • Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. 
  • Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial. 
  • Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. 
  • Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. 
  • Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Editorial comment--what can models teach us about stroke treatment? Sorting out the missing bits. 
  • Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). 
  • Effect of age on outcome with primary angioplasty versus thrombolysis. 
  • Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. 
  • Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. 
  • Effect of smoking status on response to thrombolytic therapy. 
  • Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. 
  • Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. 
  • Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. 
  • Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. 
  • Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). 
  • Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. 
  • Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. 
  • Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. 
  • Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. 
  • Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
  • Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). 
  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. 
  • Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. 
  • Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. 
  • End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. 
  • Endoluminal recanalization in a patient with phlegmasia cerulea dolens using a multimodality approach-a case report. 
  • Endovascular Thrombectomy for Anterior Circulation Stroke: Systematic Review and Meta-Analysis. 
  • Endovascular treatment of venous sinus thrombosis: a case report and review of the literature. 
  • Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks. 
  • Epidemiology of a large telestroke cohort in the Delaware valley. 
  • Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. 
  • Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. 
  • Evidence-Based Performance Measures and Outcomes in Patients With Acute Ischemic Stroke. 
  • Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. 
  • Evolution of an automated ST-segment analysis program for dynamic real-time, noninvasive detection of coronary occlusion and reperfusion. 
  • Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal journey and perspective. 
  • Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy. 
  • Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove! 
  • Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. 
  • Feasibility and Efficacy of Nurse-Driven Acute Stroke Care. 
  • Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibrinolysis or primary PCI in myocardial infarction. 
  • Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • For deep vein thrombosis, follow the randomized trials--reply. 
  • Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. 
  • Frequency of nonsystem delays in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention and implications for door-to-balloon time reporting (from the American Heart Association Mission: Lifeline program). 
  • Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • From thrombolytic megatrials to clinical policy-making: facing the facts. 
  • GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? 
  • Gender and acute myocardial infarction: is there a different response to thrombolysis? 
  • Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. 
  • Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy. Study design and technical considerations. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. 
  • Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. 
  • Grade III ischemia on presentation with acute myocardial infarction predicts rapid progression of necrosis and less myocardial salvage with thrombolysis. 
  • Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group. 
  • Guideline adjudicated fibrinolytic failure: incidence, findings, and management in a contemporary clinical trial. 
  • Guidelines for STEMI. 
  • Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. 
  • Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. 
  • Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. 
  • Guidelines on the use of thrombolytic agents in stroke. 
  • Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. 
  • Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. 
  • Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. 
  • Heparin management in acute myocardial infarction (AMI). 
  • Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. 
  • Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators. 
  • High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: results from the Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. 
  • Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. 
  • Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001-2004. 
  • How much do we gain by reducing time to reperfusion therapy? 
  • Hyperperfusion on perfusion computed tomography following revascularization for acute stroke. 
  • Hypertension with acute coronary syndrome and heart failure. 
  • ISIS-4. 
  • IV tPA for acute ischemic stroke: Times are changing. 
  • Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy. Results from the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry. 
  • Iliac vein thrombosis: feasibility assessment of randomized controlled trials of endovascular pharmacomechanical thrombolysis. 
  • Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. 
  • Impact of Institutional Volume on Outcomes of Catheter Directed Thrombolysis in the Treatment of Acute Proximal Deep Vein Thrombosis: A 6-Year US Experience (2005-2010). 
  • Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. 
  • Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry. 
  • Impact of delay in door-to-needle time on mortality in patients with ST-segment elevation myocardial infarction. 
  • Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia. 
  • Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. 
  • Impact of race on cardiac care and outcomes in veterans with acute myocardial infarction. 
  • Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Importance of early and complete reperfusion to achieve myocardial salvage after thrombolysis in acute myocardial infarction. 
  • Important patient subgroups in thrombolytic therapy. 
  • Improved outlook for patients with acute myocardial infarction: an interim progress report. 
  • Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. 
  • In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors. 
  • Inability to Consent Does Not Diminish the Desirability of Stroke Thrombolysis 
  • Incidence and clinical relevance of the occurrence of bundle-branch block in patients treated with thrombolytic therapy. 
  • Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. 
  • Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. 
  • Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. 
  • Increase in ST-segment elevation immediately after reperfusion: cause and meaning. 
  • Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis. 
  • Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. 
  • Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. 
  • Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? 
  • Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. 
  • Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. 
  • Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction. 
  • Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. 
  • International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. 
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. 
  • Intra-arterial thrombolytic therapy in peri-coronary angiography ischemic stroke. 
  • Intracranial haemorrhage with bolus thrombolytic agents. 
  • Intracranial haemorrhage with bolus thrombolytic agents. 
  • Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 
  • Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. 
  • Intraocular injection of recombinant hirudin to prevent experimental postoperative fibrin. 
  • Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. 
  • Intravenous thrombolysis in acute myocardial infarction. 
  • Intravenous tissue plasminogen activator administration in community hospitals facilitated by telestroke service. 
  • Introduction: evidence to practice in acute coronary syndromes. 
  • Is the use of t-PA as compared with streptokinase cost effective? 
  • It's a matter of time: contemporary pre-hospital management of acute ST elevation myocardial infarction. 
  • Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. 
  • Lack of progress in cardiogenic shock: lessons from the GUSTO trials. 
  • Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. (LATE Study Investigators) 
  • Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. 
  • Left circumflex occlusion in acute myocardial infarction (from the National Cardiovascular Data Registry). 
  • Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. 
  • Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. 
  • Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke. 
  • Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Major pulmonary embolism and hemodynamic stability from shunting through a patent foramen ovale. 
  • Management of infrainguinal occluded vein bypasses with a combined approach of thrombolysis and surveillance. A prospective study. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Manual high-dose regional intraoperative thrombolysis of lower extremity emboli after open repair of a ruptured abdominal aortic aneurysm. 
  • Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. 
  • Maximizing the benefits of thrombolytic therapy for acute myocardial infarction. 
  • Mechanical versus chemical thrombolysis: an in vitro differentiation of thrombolytic mechanisms. 
  • Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. 
  • Medical therapy for acute ischemic stroke. 
  • Medical, ethical and legal issues regarding thrombolytic therapy in the Jehovah's Witness. 
  • Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. 
  • Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. 
  • Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. 
  • Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. 
  • Midterm follow-up after pharmacomechanical thrombolysis for lower extremity deep venous thrombosis. 
  • Minding the stroke business. 
  • Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group). 
  • Modern medical management of acute ischemic stroke. 
  • More on the GUSTO Trial. 
  • Mortality and morbidity reduction by primary percutaneous coronary intervention is independent of the patient's age. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • Multimodal endovascular management of acute ischemic stroke in patients over 75 years old is safe and effective. 
  • Multimodal percutaneous intervention for critical venous occlusive disease. 
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Myocardial salvage after reperfusion. Observations from analysis of serial electrocardiographic and biochemical indices. 
  • Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. 
  • New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation. 
  • New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarction. 
  • New dose regimens for coronary thrombolysis. 
  • New heparin dosing recommendations for patients with acute coronary syndromes. 
  • Non-Q wave infarction after thrombolytic therapy. 
  • Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. 
  • Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. 
  • Noninvasive, medical management for non-ST-elevation acute coronary syndromes. 
  • Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. 
  • Off-hour admission and in-hospital stroke case fatality in the get with the guidelines-stroke program. 
  • One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. 
  • Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. 
  • Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? 
  • Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. 
  • Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. 
  • Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Outcomes and predictors of failure of thrombolysis for iliofemoral deep venous thrombosis. 
  • Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • PCI at non-PCI centres: immediate or rescue? 
  • Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group. 
  • Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. 
  • Patient safety in trials of therapy for acute ischemic stroke. 
  • Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. 
  • Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). 
  • Perception Versus Actual Performance in Timely Tissue Plasminogen Activation Administration in the Management of Acute Ischemic Stroke. 
  • Percutaneous interventions on the hemodialysis reliable outflow vascular access device. 
  • Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. 
  • Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. 
  • Peripheral vascular complications during transcatheter aortic valve replacement: management and potential role of chronic steroid use. 
  • Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. 
  • Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. 
  • Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III. 
  • Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: safety and feasibility study. 
  • Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy. 
  • Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial. 
  • Platelet function and fibrinolytic agents: two sides of a coin? 
  • Point of view: use of left ventricular function as prognostic factor. 
  • Postcoronary thrombolysis management. 
  • Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. 
  • Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease. 
  • Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. 
  • Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. 
  • Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study. 
  • Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram. 
  • Prediction of the infarct-related artery in acute myocardial infarction by a scoring system using summary ST-segment and T-wave changes. 
  • Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. 
  • Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. 
  • Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. 
  • Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. 
  • Predictors of outcome of reperfusion therapy. 
  • Predictors of rapid brain imaging in acute stroke: analysis of the Get With the Guidelines-Stroke program. 
  • Pregnancy and thrombotic risk. 
  • Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive Instrument (TPI) Project results. 
  • Prevention of Cardiogenic Shock After Acute Myocardial Infarction. 
  • Primary PCI in ST-segment elevation myocardial infarction. 
  • Primary angioplasty vs thrombolysis in elderly patients. 
  • Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. 
  • Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. 
  • Primary upper-extremity deep venous thrombosis. 
  • Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. 
  • Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. 
  • Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. 
  • Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. 
  • Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). 
  • Prognostic value of clinical markers of reperfusion in patients with acute myocardial infarction treated by thrombolytic therapy. 
  • Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. 
  • Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Prosthetic valve thrombosis: when and how should we lyse? 
  • Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR). 
  • Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. 
  • Pursuing progress in acute coronary syndromes. 
  • QT prolongation and dispersion in myocardial ischemia and infarction. 
  • Quality of care and outcomes for in-hospital ischemic stroke: findings from the National Get With The Guidelines-Stroke. 
  • Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. 
  • Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. 
  • Race/ethnicity, quality of care, and outcomes in ischemic stroke. 
  • Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. 
  • Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). 
  • Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Radiologic intervention in the acute stroke patient. 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Rapid and progressive venous thrombosis after occlusion of high-flow arteriovenous fistula. 
  • Rapid intra-arterial thrombolysis in stent-associated retinal artery occlusion. 
  • Ratio of ST-segment and myoglobin slopes to estimate myocardial salvage during thrombolytic therapy for acute myocardial infarction. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. 
  • Recent update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: role of antiplatelet therapy. 
  • Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. 
  • Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. 
  • Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. 
  • Recurrent ischemia after thrombolysis for acute myocardial infarction. 
  • Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. 
  • Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. 
  • Reducing system delays in treatment of ST elevation myocardial infarction and confronting the challenges of late presentation in low and middle-income countries. 
  • Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. 
  • Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. 
  • Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. 
  • Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction Trials). 
  • Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. 
  • Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. 
  • Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. 
  • Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship between community hospital versus pre-hospital location of randomisation and clinical outcomes in ST-elevation myocardial infarction patients: insights from the Stream study. 
  • Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. 
  • Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trials. 
  • Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. 
  • Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. 
  • Relationships Between Baseline Q Waves, Time From Symptom Onset, and Clinical Outcomes in ST-Segment-Elevation Myocardial Infarction Patients: Insights From the Vital Heart Response Registry. 
  • Reperfusion and revascularization strategies for coronary artery disease in women. 
  • Reperfusion in waiting: what queue should we join? 
  • Reperfusion paradox in ST-segment elevation myocardial infarction. 
  • Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. 
  • Reperfusion strategies for acute myocardial infarction in the elderly: benefits and risks. 
  • Reperfusion strategies in acute coronary syndromes. 
  • Rescue thrombolysis: resolution of intraglomerular thrombi after donation after circulatory death. 
  • Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. 
  • Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. 
  • Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). 
  • Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. 
  • Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. 
  • Risk stratification and therapeutic decision making in acute coronary syndromes. 
  • Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials. 
  • ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
  • Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. 
  • Safety and efficacy of catheter directed thrombolysis in children with deep venous thrombosis. 
  • Safety of Computed Tomographic Angiography in the Evaluation of Patients With Acute Stroke: A Single-Center Experience. 
  • Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty. 
  • Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction. 
  • Sex differences in utilization and outcomes of catheter-directed thrombolysis in patients with proximal lower extremity deep venous thrombosis - Insights from the Nationwide Inpatient Sample. 
  • Should reperfusion strategies in myocardial infarction be modified for the very elderly? 
  • Should we just let the anticoagulation service do it? 
  • Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Significance of hemoptysis following thrombolytic therapy for acute myocardial infarction. 
  • Silastic cuffed catheters for hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. 
  • Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. 
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 
  • Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. 
  • State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction. 
  • Stent-assisted basilar reconstruction for a traumatic vertebral dissection with a large basilar artery thrombosis. 
  • Strategies for optimizing outcomes in the NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report. 
  • Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. 
  • Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. 
  • Streptokinase promotes development of dipeptidyl peptidase IV (CD26) autoantibodies after fibrinolytic therapy in myocardial infarction patients. 
  • Streptokinase versus alteplase in acute myocardial infarction. 
  • Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. 
  • Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. 
  • Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group. 
  • Successful revascularization for delayed presentation of radiation-induced distal upper extremity ischemia. 
  • Supplement on acute coronary syndromes: introduction. 
  • Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. 
  • Surgical pulmonary embolectomy and catheter-based therapies for acute pulmonary embolism: A contemporary systematic review. 
  • Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • TIMI IIB follow-up. Lessons for clinicians and investigators. 
  • TIMI frame count: a quantitative method of assessing coronary artery flow. 
  • TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. 
  • Targeting telestroke: benchmarking time performance in telestroke consultations. 
  • Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. 
  • Temporal and Provincial Variation in Ambulance Use Among Patients Who Present to Acute Care Hospitals With ST-Elevation Myocardial Infarction. 
  • Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. 
  • Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. 
  • Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. 
  • Temporary endovascular bypass: rescue technique during mechanical thrombolysis. 
  • Testing the Presumption of Consent to Emergency Treatment for Acute Ischemic Stroke 
  • The Choice Is Reperfusion Therapy: But Which One? 
  • The Comparison of the Outcomes between Primary PCI, Fibrinolysis, and No Reperfusion in Patients ≥ 75 Years Old with ST-Segment Elevation Myocardial Infarction: Results from the Chinese Acute Myocardial Infarction (CAMI) Registry. 
  • The Fuzzy Math of Anticoagulation and Access Site: When 1 + 1 Does Not Always Equal 2. 
  • The Need for Speed. 
  • The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. 
  • The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. 
  • The emerging role of myoglobin for risk stratification. 
  • The everlasting effect of primary percutaneous coronary intervention--even after transport? 
  • The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. 
  • The exclusion of women from clinical trials of thrombolytic therapy: implications for developing the thrombolytic predictive instrument database. 
  • The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. 
  • The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. 
  • The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. 
  • The need for wider utilization of thrombolytic therapy. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The platelet-related effects of tenecteplase versus alteplase versus reteplase. 
  • The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? 
  • The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. 
  • The risk of stroke after thrombolytic therapy. 
  • The role of angioplasty after failed thrombolysis for acute myocardial infarction. 
  • The role of angioplasty after successful thrombolysis for acute myocardial infarction. 
  • The role of platelet receptors and adhesion molecules in coronary artery disease. 
  • The role of prolonged thrombolytic infusions and transesophageal echocardiography in thrombosed prosthetic heart valves: case report and review of the literature. 
  • The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock. 
  • The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. 
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. 
  • Thrombolysis for acute ischemic stroke in patients with cancer: a population study. 
  • Thrombolysis in acute peripheral arterial occlusion: predictors of immediate success. 
  • Thrombolysis in stroke: a medicolegal quagmire. 
  • Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke. 
  • Thrombolysis is an Independent Risk Factor for Poor Outcome After Carotid Revascularization. 
  • Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock. 
  • Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Thrombolytic Therapy for Acute Myocardial Infarction : A Review. 
  • Thrombolytic therapy for acute myocardial infarction: GUSTO criticized. 
  • Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. 
  • Thrombolytic therapy for arterial thrombosis. 
  • Thrombolytic therapy for elderly patients. 
  • Thrombolytic therapy for myocardial infarction. 
  • Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices. 
  • Thrombolytic therapy for venous thromboembolism: current clinical practice. 
  • Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Thrombolytic therapy in central retinal artery occlusion: cutting edge therapy, standard of care therapy, or impractical therapy? 
  • Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. 
  • Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. 
  • Thrombolytic therapy: time to treatment. 
  • Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. 
  • Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. 
  • Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. 
  • Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. 
  • Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. 
  • Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. 
  • Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. 
  • Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. 
  • Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries. 
  • Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. 
  • Timely Reperfusion in Stroke and Myocardial Infarction Is Not Correlated: An Opportunity for Better Coordination of Acute Care. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. 
  • Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. 
  • Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. 
  • Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. 
  • Treatment of acute myocardial infarction. 
  • Treatment of cerebral vasospasm after subarachnoid hemorrhage--a review. 
  • Treatment of dural sinus thrombosis by urokinase infusion. 
  • Treatment of patients with myocardial infarction who present with a paced rhythm. 
  • Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. 
  • Treatment of venous thromboembolism: guidelines translated for the clinician. 
  • Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. 
  • Trends in endovascular therapy and clinical outcomes within the nationwide Get With The Guidelines-Stroke registry. 
  • Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. 
  • Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. 
  • Two urokinase dose regimens in native arterial and graft occlusions: initial results of a prospective, randomized clinical trial. 
  • Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. Thrombolysis and Angioplasty Study Group. 
  • Ultrasound accelerated catheter directed thrombolysis for pulmonary embolus and right heart thrombus secondary to transvenous pacing wires. 
  • Ultrasound-mediated drug delivery. 
  • Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. 
  • Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. 
  • Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. 
  • Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. 
  • Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). 
  • Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. The TAMI Study Group. 
  • Usefulness of frequent arrhythmias after epicardial recanalization in anterior wall acute myocardial infarction as a marker of cellular injury leading to poor recovery of left ventricular function. 
  • Using Data to Guide Anticoagulation in Patients With Atrial Fibrillation: Does the Analysis Fit the Question? 
  • Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? 
  • Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. 
  • Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. 
  • Venous thromboembolism in the Get With The Guidelines-Stroke acute ischemic stroke population: incidence and patterns of prophylaxis. 
  • Volume-outcome relationship in acute myocardial infarction: the balloon and the needle. 
  • What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? 
  • Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. 
  • [Canadian Consensus Conference on Coronary Thrombolysis--current aspects]. 
  • [Serum creatine kinase isoenzyme MB and myoglobin in patients with acute myocardial infarction and coronary reperfusion]. 
  • [Serum myoglobin as a non-invasive marker of coronary reperfusion after intravenous thrombolytic therapy in patients with acute myocardial infarction]. 
  • mStroke: "Mobile Stroke"-Improving Acute Stroke Care with Smartphone Technology. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Kim, Charles Yoon, Associate Professor of Radiology, Radiology, Interventional Radiology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Distinguished Professor of Cardiology, Medicine, Clinical Pharmacology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Toth, Cynthia Ann, Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology, Ophthalmology, Vitreoretinal Diseases & Surgery